Distribution of lifestyle and emerging risk factors by 10-year risk for coronary heart disease

European Journal of Preventive Cardiology

Volumn 13, Issue 5, 2006, Pages 745-752

  Ajani, Umed A ^a   Ford, Earl S ^a   Mcguire, Lisa C ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

coronary heart disease; risk factor distribution

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GLYCOSYLATED HEMOGLOBIN; HOMOCYSTEINE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY RISK; FEMALE; FIBRINOGEN BLOOD LEVEL; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; LEUKOCYTE COUNT; LIFESTYLE; MALE; MICROALBUMINURIA; OBESITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; WAIST CIRCUMFERENCE;

ADULT; AGED; AGING; CORONARY DISEASE; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; RISK FACTORS; SEX CHARACTERISTICS;

EID: 33749032087     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/01.hjr.0000230099.70900.f6     Document Type: Article

References (33)

1. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.
3. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199–270.
4. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(Suppl 2):S1–S29.
5. Voss R, Cullen P, Schulte H, Assmann G. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002; 31: 1253–1262.
6. Eckel RH. Obesity and heart disease: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1997; 96: 3248–3250.
7. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995; 311: 158–161.
8. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ 1995; 311: 1401–1405.
9. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996; 144: 537–547.
10. Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 2001; 47: 28–30.
11. Ridker PM. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am Heart J 2004; 148: S19–S26.
12. Madjid M, Awan I, Willerson JT, Casscells SW. Leukocyte count and coronary heart disease: implications for risk assessment. J Am Coll Cardiol 2004; 44: 1945–1956.
13. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477–1482.
14. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268: 877–881.
15. Giles WH, Croft JB, Greenlund KJ, Ford ES, Kittner SJ. Association between total homocyst(e)ine and the likelihood for a history of acute myocardial infarction by race and ethnicity: Results from the Third National Health and Nutrition Examination Survey. Am Heart J 2000; 139: 446–453.
16. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 2004; 141: 413–420.
17. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421–431.
18. Vitelli LL, Shahar E, Heiss G, McGovern PG, Brancati FL, Eckfeldt JH, et al Glycosylated hemoglobin level and carotid intimal-medial thickening in nondiabetic individuals. The Atherosclerosis Risk in Communities Study. Diabetes Care 1997; 20: 1454–1458.
19. Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC. Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992; 41: 202–208.
20. Mattix HJ, Hsu CY, Shaykevich S, Curhan G. Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race. J Am Soc Nephrol 2002; 13: 1034–1039.
21. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2004; 92: S59–S62.
22. Linton MF, Fazio S. A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol 2003; 92: 19i–26i.
23. Centers for Disease Control and Prevention. NHANES 1999–2000 Data Files http://www.cdc.gov/nchs/about/major/nhanes/NHANES99_00.htm [Accessed 20 January 2005].
24. Centers for Disease Control and Prevention. NHANES 2001–2002 Data Files http://www.cdc.gov/nchs/about/major/nhanes/nhanes01–02.htm [Accessed 20 January 2005].
25. Centers for Disease Control and Prevention. NHANES laboratory/medical technologists procedure manual; http://www.cdc.gov/nchs/data/nhanes/lab1–6.pdf [Accessed 20 January 2005].
26. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499–511.
27. American Society of Human Genetics/American College of Medical Genetics Test and Transfer Committee Working Group. Measurement and use of total plasma homocysteine. Am J Hum Genet 1998; 63: 1541–1543.
28. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004–1010.
29. Research Triangle Institute. SUDAAN user's manual. Release 8.0. Research Triangle Park, North Carolina: Research Triangle Institute; 2002.
30. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161–165.
31. Ajani UA, Ford ES, Mokdad AH. Prevalence of high C-reactive protein in persons with serum lipid concentrations within recommended values. Clin Chem 2004; 50: 1618–1622.
32. Asselbergs FW, Hillege HL, van Gilst WH. Framingham score and microalbuminuria: combined future targets for primary prevention? Kidney Int Suppl. 2004; 92: S111–S114.
33. Wilson PW. Assessing coronary heart disease risk with traditional and novel risk factors. Clin Cardiol 2004; 27: III7–III11.